logo
Share SHARE
FONT-SIZE Plus   Neg

XenoPort Gets U.S. Patent Directed To Composition And Formulations Of XP23829

XenoPort Inc. (XNPT) said it was awarded U.S. Patent 8,148,414 for "Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use." Subject to potential Hatch-Waxman patent term extensions, the term of the patent extends until 2029.

The patent is directed to the XP23829 compound, analogs thereof and formulations thereof, XenoPort added. A related U.S. patent application directed to therapeutic uses of XP23829 is currently pending. XP23829 is a prodrug of methyl hydrogen fumarate, also called as monomethyl fumarate or MMF. In cell- and animal-based models, MMF has been shown to exhibit immuno-modulatory properties and inhibit damage from oxidative stress.

XenoPort, which owns all rights to XP23829, plans to file an Investigational New Drug Application for XP23829 for the treatment of relapsing remitting MS with the U.S. Food and Drug Administration in the second quarter of 2012 and expects to initiate human clinical trials later this year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Zynga Inc. (ZNGA) on Thursday reported a first-quarter loss that narrowed from a year ago, reflecting an increase in revenues despite continued drop in user-base. Earnings for the quarter trumped analysts estimates, as did revenues, sending the company's shares up 13 percent in extended trading hours. San... Shares of Fitbit Inc. (FIT) slumped over 12 percent in extended hours trading after the maker of wearable technology reported a drop in first-quarter profit hurt largely by a surge in operating costs. The company also detailed a weak outlook for the second quarter. Fitbit's profit for the first-quarter... Twenty-First Century Fox Inc., (FOXA, FOX) on Wednesday reported a third-quarter profit that dropped from last year, as an increase in revenues were offset by higher operating costs. Earnings for the quarter came in line with Wall Street estimates, while revenues trumped expectations. Fox's third-quarter...
comments powered by Disqus
Follow RTT